News: PIQ Proteomics International Laboratories Launches PromarkerD In Spain Under Deal With Patia..., page-19

Found the above on the Patia website as part of an announcement regarding their upcoming presentation at the 2019 EASD conference (European Associate for the Study of Diabetes) http://www.patiadiabetes.com/en/patia-pioneering-t2d-and-gdm-prevention-and-intervention/

This conference is a nice platform to further market the commercialization into Europe.
The diabetic population is in excess of 50 Million across EUR.

I have been trying to do the math on what the potential revenue figure would like upon a successful global roll-out.
I think $10M p/a from royalties at $5 per test is quite achievable in the near term (1-5years). They mentioned test would sell for US$50 with royalties at 5-15%.

I recall seeing PIQ making claims of 100M+ in potential revenue, but I think that's a bit of hype but does have some substance given there are over 400 million people diagnosed with diabetes worldwide. Can you image, even at 10% penetration on the global market - we would be looking at revenues of $200M+.

I am sticking with my modest $10m near term which would give us a primitive valuation of at least $100-200million based on just the PromarkerD revenue alone.

Have a great weekend folks!